Page values for "Norethindrone"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Norethindrone (norethisterone outside US)
brand	`String`	Aygestin (5 mg, Rx); Camila, Errin, Heather, Jolivette, Nor-QD, Ortho Micronor, Sharobel (0.35 mg POPs); component of many COCs
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:Progestins\|Progestin (synthetic progestogen)]] • [[:Category:Hormonal_contraceptives\|Hormonal contraceptive]] • [[:Category:Sex_hormones\|Sex hormone]]
mechanism	`String`	'"`UNIQ--vote-000013EE-QINU`"' Higher-dose Aygestin (5 mg) achieves more reliable ovulation suppression and is used for endometriosis and DUB. POP requires strict daily timing because the 24-hour cervical-mucus effect window is narrower than COC'"`UNIQ--ref-000013EF-QINU`"'.
uses	`String`	'"`UNIQ--vote-000013F0-QINU`"', '"`UNIQ--vote-000013F1-QINU`"', '"`UNIQ--vote-000013F2-QINU`"', '"`UNIQ--vote-000013F3-QINU`"', '"`UNIQ--vote-000013F4-QINU`"'
starting_dose	`String`	POP: 0.35 mg PO daily continuously (no placebo week); high-dose 5 mg Aygestin for amenorrhea/endometriosis 5-10 mg/d
preparations	`String`	0.35 mg POP tablets; 5 mg tablets (Aygestin); component of COCs and combination HRT
fda_max	`String`	Indication-specific
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Oral
onset	`String`	Contraception within 48 hours of starting (POP); endometrial effects days
duration	`String`	~24 hours per dose (strict timing required for POP — within 3-hour window each day)
halflife	`String`	~8 hours'"`UNIQ--ref-000013F5-QINU`"'
bioavailability	`String`	~65% (oral)'"`UNIQ--ref-000013F6-QINU`"'
pregnancy	`String`	Contraindicated in known pregnancy (Aygestin); the 0.35 mg POP is not teratogenic and does not need to be discontinued before conception planning.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed\|citation needed]]]</sup>
legal	`String`	[[USLegal:Prescription only\|Rx-only]] in US (note: norgestrel 0.075 mg POP is now OTC as Opill since 2023, but norethindrone POP remains Rx)